Pain and Smoking Study 2.0: A Randomized Clinical Trial of Smoking Cessation Among Veterans With Chronic Pain
Start Date
9/21/2026
Completion Date
5/31/2028
Summary
PASS2 aims to expand upon the recently completed study (PASS intervention), which tested the telephone delivery of a cognitive behavioral intervention (CBI). This study will use nightly surveys to optimize the intervention's effectiveness for smoking cessation among Veteran smokers with chronic pain.
Detailed Description
Veterans with chronic pain represent an important population in which to focus smoking cessation efforts. Smoking cessation among patients with chronic medical illnesses substantially decreases morbidity and mortality; yet, many patients (\>50%) with chronic pain continue to smoke. This study aims to: 1. Determine whether the existing integrated pain and smoking cessation (PASS intervention) augmented with nightly surveys (PASS2) is superior to treatment as usual (e.g., referral to standard VA smoking cessation clinic) enhanced with pharmacotherapy tele-consult (E-TAU) at 4 months and 10 months (primary endpoint) on cigarette abstinence rates among non-depressed Veterans with chronic pain. 2. Determine whether PASS2 is superior to E-TAU at 4 months and 10 months (primary endpoint) on pain interference. 3. Examine critical components of the intervention process to inform future program implementation.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
PASS2
Treatment as Usual
Conditions
Locations
VA Connecticut Healthcare System West Haven Campus, West Haven, CT
West Haven, Connecticut 06516-2770
United States